JPWO2022160057A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022160057A5 JPWO2022160057A5 JP2023545809A JP2023545809A JPWO2022160057A5 JP WO2022160057 A5 JPWO2022160057 A5 JP WO2022160057A5 JP 2023545809 A JP2023545809 A JP 2023545809A JP 2023545809 A JP2023545809 A JP 2023545809A JP WO2022160057 A5 JPWO2022160057 A5 JP WO2022160057A5
- Authority
- JP
- Japan
- Prior art keywords
- subunit
- nanocage
- fusion protein
- monomer
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002091 nanocage Substances 0.000 claims description 194
- 102000037865 fusion proteins Human genes 0.000 claims description 164
- 108020001507 fusion proteins Proteins 0.000 claims description 164
- 239000000178 monomer Substances 0.000 claims description 111
- 239000000427 antigen Substances 0.000 claims description 67
- 102000036639 antigens Human genes 0.000 claims description 67
- 108091007433 antigens Proteins 0.000 claims description 67
- 239000012634 fragment Substances 0.000 claims description 51
- 108010002084 Apoferritins Proteins 0.000 claims description 43
- 102000000546 Apoferritins Human genes 0.000 claims description 43
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 10
- 239000000539 dimer Substances 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 6
- 241000233866 Fungi Species 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 208000026278 immune system disease Diseases 0.000 claims description 6
- 239000012678 infectious agent Substances 0.000 claims description 6
- 244000045947 parasite Species 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 108010068996 6,7-dimethyl-8-ribityllumazine synthase Proteins 0.000 claims description 4
- 101710132601 Capsid protein Proteins 0.000 claims description 4
- 108010058432 Chaperonin 60 Proteins 0.000 claims description 4
- 102000006303 Chaperonin 60 Human genes 0.000 claims description 4
- 101710094648 Coat protein Proteins 0.000 claims description 4
- 101710088194 Dehydrogenase Proteins 0.000 claims description 4
- -1 E2P Proteins 0.000 claims description 4
- 102000008857 Ferritin Human genes 0.000 claims description 4
- 108050000784 Ferritin Proteins 0.000 claims description 4
- 238000008416 Ferritin Methods 0.000 claims description 4
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims description 4
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 4
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 4
- 101710125418 Major capsid protein Proteins 0.000 claims description 4
- 101710141454 Nucleoprotein Proteins 0.000 claims description 4
- 101710083689 Probable capsid protein Proteins 0.000 claims description 4
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 238000001338 self-assembly Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 1
- 241001112090 Pseudovirus Species 0.000 description 12
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 8
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 230000035772 mutation Effects 0.000 description 6
- 108091006047 fluorescent proteins Proteins 0.000 description 4
- 102000034287 fluorescent proteins Human genes 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- RQVYBGPQFYCBGX-UHFFFAOYSA-N ametryn Chemical compound CCNC1=NC(NC(C)C)=NC(SC)=N1 RQVYBGPQFYCBGX-UHFFFAOYSA-N 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 239000012216 imaging agent Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163142704P | 2021-01-28 | 2021-01-28 | |
| US63/142,704 | 2021-01-28 | ||
| PCT/CA2022/050122 WO2022160057A1 (en) | 2021-01-28 | 2022-01-28 | Multabody constructs, compositions, and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024504777A JP2024504777A (ja) | 2024-02-01 |
| JPWO2022160057A5 true JPWO2022160057A5 (https=) | 2025-02-04 |
| JP2024504777A5 JP2024504777A5 (https=) | 2025-02-04 |
Family
ID=82652697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023545809A Pending JP2024504777A (ja) | 2021-01-28 | 2022-01-28 | Ｍｕｌｔａｂｏｄｙ構築物、組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240317842A1 (https=) |
| EP (1) | EP4284840A4 (https=) |
| JP (1) | JP2024504777A (https=) |
| KR (1) | KR20230136166A (https=) |
| CN (1) | CN117157328A (https=) |
| AU (1) | AU2022212978A1 (https=) |
| CA (1) | CA3208446A1 (https=) |
| MX (1) | MX2023008912A (https=) |
| WO (1) | WO2022160057A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240032875A (ko) * | 2021-07-12 | 2024-03-12 | 더 호스피탈 포 식 칠드런 | 최적화된 멀타바디 작제물, 조성물 및 방법 |
| MX2024003140A (es) * | 2021-09-13 | 2024-06-24 | Hospital For Sick Children | Construcciones, composiciones y metodos de multabody optimizados. |
| KR20240101591A9 (ko) * | 2021-10-16 | 2025-12-10 | 더 호스피탈 포 식 칠드런 | 변형된 멀타바디 작제물, 조성물 및 방법 |
| WO2023060359A1 (en) * | 2021-10-16 | 2023-04-20 | The Hospital For Sick Children | Modified multabody constructs, compositions, and methods targeting sars-cov-2 |
| CN120603858A (zh) * | 2022-12-18 | 2025-09-05 | 锐迪恩特生物治疗股份有限公司 | 多价造血细胞接合剂或激活剂 |
| CN120771308B (zh) * | 2025-09-04 | 2025-12-12 | 中山大学 | 一种具有缓释效应的蛋白笼纳米药物及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019023811A1 (en) * | 2017-08-04 | 2019-02-07 | The Hospital For Sick Children | NANOPARTICLE PLATFORM FOR ANTIBODY AND VACCINE DELIVERY |
| AU2019301160A1 (en) * | 2018-07-11 | 2021-02-25 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered Fc-antigen binding domain constructs targeted to CTLA-4 |
| JP2022543070A (ja) * | 2019-08-01 | 2022-10-07 | ザ ホスピタル フォー シック チルドレン | 多価及び多重特異性ナノ粒子プラットフォーム及び方法 |
| MX2023004023A (es) * | 2020-10-09 | 2023-07-07 | Hospital For Sick Children | Polipéptidos que eligen como objetivo a sars-cov-2 y composiciones y métodos relacionados. |
-
2022
- 2022-01-28 AU AU2022212978A patent/AU2022212978A1/en active Pending
- 2022-01-28 EP EP22744974.1A patent/EP4284840A4/en active Pending
- 2022-01-28 WO PCT/CA2022/050122 patent/WO2022160057A1/en not_active Ceased
- 2022-01-28 KR KR1020237028653A patent/KR20230136166A/ko active Pending
- 2022-01-28 CA CA3208446A patent/CA3208446A1/en active Pending
- 2022-01-28 MX MX2023008912A patent/MX2023008912A/es unknown
- 2022-01-28 CN CN202280021845.1A patent/CN117157328A/zh active Pending
- 2022-01-28 US US18/263,217 patent/US20240317842A1/en active Pending
- 2022-01-28 JP JP2023545809A patent/JP2024504777A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7328267B2 (ja) | Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質 | |
| TWI856979B (zh) | 三特異性抗ｃｄ３８、抗ｃｄ２８和抗ｃｄ３結合蛋白和用於治療病毒感染的使用方法 | |
| TWI689518B (zh) | 特異性結合人ｉｌ-１７ａ的分離的單株抗體 | |
| JP2019533441A5 (https=) | ||
| CA3199447A1 (en) | Fusions with cd8 antigen binding molecules for modulating immune cell function | |
| JP2019519527A (ja) | 操作されたＦｃコンストラクトに関する組成物及び方法 | |
| JP2020509756A5 (https=) | ||
| JP2017523814A5 (https=) | ||
| JP2010532764A5 (https=) | ||
| CN103154029A (zh) | 抗人tweak的抗体及其用途 | |
| JP2024504777A (ja) | Ｍｕｌｔａｂｏｄｙ構築物、組成物および方法 | |
| JP2021512159A5 (https=) | ||
| US20240101639A1 (en) | FC Monomer Polypeptide and Application Thereof | |
| JP2023537470A (ja) | ウイルス治療における多方向バイオ輸送のための材料及び方法 | |
| JP7676316B2 (ja) | Ｈｉｖ感染症の処置のためのクロスオーバー二重可変ドメイン（ｃｏｄｖ）フォーマットを使用した三重特異性および／または三価結合性タンパク質 | |
| JPWO2021116182A5 (https=) | ||
| US20220144956A1 (en) | HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII | |
| JPWO2022160057A5 (https=) | ||
| US20240034815A1 (en) | Heterodimeric antibodies that bind cd3 and gpc3 | |
| TW202325744A (zh) | 用於ｈｉｖ之抗原結合多肽、抗原結合多肽複合物及其使用方法 | |
| CA2789328A1 (en) | Multimeric proteins comprising immunoglobulin constant domains | |
| Wang et al. | New directions for half-life extension of protein therapeutics: the rise of antibody Fc domains and fragments | |
| US20260098090A1 (en) | Fusions with cd8 antigen binding molecules for treating chronic viral infection | |
| US20250339519A1 (en) | Combination of cytokine fusion proteins with cd8 antigen binding molecules | |
| JPWO2021052349A5 (https=) |